TY - JOUR
T1 - Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia
T2 - a population-based study
AU - Zand Irani, Mudar
AU - Jones, Michael P.
AU - Halland, Magnus
AU - Herrick, Linda
AU - Choung, Rok Seon
AU - Saito Loftus, Yuri A.
AU - Walker, Marjorie M.
AU - Murray, Joseph A.
AU - Talley, Nicholas J.
N1 - Funding Information:
We acknowledge Professor Simon Keely for his support of Mudar Zand Irani as a PhD supervisor. This study acknowledges support from the National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Digestive Health and an NHMRC investigator grant to Dr Talley. Declaration of personal interests: Dr Nicholas J. Talley reports personal fees from Allakos, from Aviro Health, from Antara Life Sciences, from Arlyx from Bayer, from Danone, from Planet Innovation, from Takeda, from Viscera Labs, from two XAR, from Viscera Labs, from Dr Falk Pharma, from Censa, from Cadila Pharmaceuticals, from Progenity Inc, from Sanofi-aventis, from Glutagen, from ARENA Pharmaceuticals, from IsoThrive, from BluMaiden, from RosePharma, from Intrinsic Medicine, from OzSage, non-financial support from HVN National Science Challenge NZ, outside the submitted work; In addition, NJT has a patent Biomarkers of IBS licensed (#12735358.9-1405/2710383 and (#12735358.9-1405/2710384), a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent NTU Ref: TD/129/17 ‘Microbiota Modulation Of BDNF Tissue Repair Pathway’ issued and copyright Nepean Dyspepsia Index (NDI) 1998 and Editorial: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). NJT participates Committees: Australian Medical Council (AMC) Council Member (2016-2019), MBS Review Taskforce (2016-2020), NHMRC Principal Committee, Research Committee (2016-2021), Asia Pacific Association of Medical Journal Editors (APAME) (current), GESA Board Member (2017-2019). NJT Misc: Avant Foundation (judging of research grants) (2019). NJT community and patient advocacy groups: Advisory Board, IFFGD (International Foundation for Functional GI Disorders). NJT acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. NJT holds an NHMRC Investigator grant. Dr. Joseph Murray has received study grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenics, Johnson & Johnson, Kanyos/Anakion, Takeda Pharmaceutical, Allakos, Oberkotter and Cour; consultancy fees from Bionix, UKKO, Dren Bio, Dr. Schar USA, Chugai Pharma; holds patents licensed to Evelo Biosciences; and receives royalties from Torax Medical. MZI, MMW, MPJ, LH, MH, RSC and YASL: no disclosures.
Funding Information:
Dr Nicholas J. Talley reports personal fees from Allakos, from Aviro Health, from Antara Life Sciences, from Arlyx from Bayer, from Danone, from Planet Innovation, from Takeda, from Viscera Labs, from two XAR, from Viscera Labs, from Dr Falk Pharma, from Censa, from Cadila Pharmaceuticals, from Progenity Inc, from Sanofi‐aventis, from Glutagen, from ARENA Pharmaceuticals, from IsoThrive, from BluMaiden, from RosePharma, from Intrinsic Medicine, from OzSage, non‐financial support from HVN National Science Challenge NZ, outside the submitted work; In addition, NJT has a patent Biomarkers of IBS licensed (#12735358.9‐1405/2710383 and (#12735358.9‐1405/2710384), a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent NTU Ref: TD/129/17 ‘Microbiota Modulation Of BDNF Tissue Repair Pathway’ issued and copyright Nepean Dyspepsia Index (NDI) 1998 and Editorial: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). NJT participates Committees: Australian Medical Council (AMC) Council Member (2016‐2019), MBS Review Taskforce (2016‐2020), NHMRC Principal Committee, Research Committee (2016‐2021), Asia Pacific Association of Medical Journal Editors (APAME) (current), GESA Board Member (2017‐2019). NJT Misc: Avant Foundation (judging of research grants) (2019). NJT community and patient advocacy groups: Advisory Board, IFFGD (International Foundation for Functional GI Disorders). NJT acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. NJT holds an NHMRC Investigator grant. Dr. Joseph Murray has received study grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenics, Johnson & Johnson, Kanyos/Anakion, Takeda Pharmaceutical, Allakos, Oberkotter and Cour; consultancy fees from Bionix, UKKO, Dren Bio, Dr. Schar USA, Chugai Pharma; holds patents licensed to Evelo Biosciences; and receives royalties from Torax Medical. MZI, MMW, MPJ, LH, MH, RSC and YASL: no disclosures. Declaration of personal interests:
Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Rumination syndrome is a functional gastroduodenal disorder characterised by effortless regurgitation of recently ingested food. Emerging evidence reports duodenal eosinophilic inflammation in a subset, suggesting a shared pathophysiology with functional dyspepsia (FD). Aim: To assess the clinical features of rumination syndrome and FD in a community-based study. Methods: We mailed a survey assessing gastrointestinal symptoms, diet and psychological symptoms to 9835 residents of Olmsted County, MN, USA in 2017-2018; diagnostic codes were obtained from linked clinical records. The two disorders were assessed as mutually exclusive in ‘pure’ forms with a separate overlap group, all compared to a control group not meeting criteria for either. Prevalence of associations, and univariate and independent associations with predictors were assessed by logistic regression. Results: Prevalence of rumination syndrome and FD were 5.8% and 7.1%, respectively; the overlap was 3.83-times more likely than expected by chance. Independent predictors for rumination (odds ratio (OR), 95% confidence interval (CI)) were female gender (1.79, 1.21-2.63), smoking (1.89, 1.28-2.78), gluten-free diet (1.58, 1.14-2.19), allergic rhinitis (1.45, 1.01-2.08) and depression (1.10, 1.05-1.16). FD was independently associated with female gender, depression, non-coeliac wheat sensitivity, migraine, irritable bowel syndrome and somatic symptoms. A similar reported efficacy (≥54%) of low fat or dairy-free diets was found with both disorders (P = 0.53 and P = 1.00, respectively). The strongest independent associations with overlapping FD and rumination syndrome were a history of rheumatoid arthritis (3.93, 1.28-12.06) and asthma (3.02, 1.44-6.34). Conclusion: Rumination syndrome overlaps with FD with a shared risk factor profile, suggesting a common pathophysiology.
AB - Background: Rumination syndrome is a functional gastroduodenal disorder characterised by effortless regurgitation of recently ingested food. Emerging evidence reports duodenal eosinophilic inflammation in a subset, suggesting a shared pathophysiology with functional dyspepsia (FD). Aim: To assess the clinical features of rumination syndrome and FD in a community-based study. Methods: We mailed a survey assessing gastrointestinal symptoms, diet and psychological symptoms to 9835 residents of Olmsted County, MN, USA in 2017-2018; diagnostic codes were obtained from linked clinical records. The two disorders were assessed as mutually exclusive in ‘pure’ forms with a separate overlap group, all compared to a control group not meeting criteria for either. Prevalence of associations, and univariate and independent associations with predictors were assessed by logistic regression. Results: Prevalence of rumination syndrome and FD were 5.8% and 7.1%, respectively; the overlap was 3.83-times more likely than expected by chance. Independent predictors for rumination (odds ratio (OR), 95% confidence interval (CI)) were female gender (1.79, 1.21-2.63), smoking (1.89, 1.28-2.78), gluten-free diet (1.58, 1.14-2.19), allergic rhinitis (1.45, 1.01-2.08) and depression (1.10, 1.05-1.16). FD was independently associated with female gender, depression, non-coeliac wheat sensitivity, migraine, irritable bowel syndrome and somatic symptoms. A similar reported efficacy (≥54%) of low fat or dairy-free diets was found with both disorders (P = 0.53 and P = 1.00, respectively). The strongest independent associations with overlapping FD and rumination syndrome were a history of rheumatoid arthritis (3.93, 1.28-12.06) and asthma (3.02, 1.44-6.34). Conclusion: Rumination syndrome overlaps with FD with a shared risk factor profile, suggesting a common pathophysiology.
UR - http://www.scopus.com/inward/record.url?scp=85116569571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116569571&partnerID=8YFLogxK
U2 - 10.1111/apt.16630
DO - 10.1111/apt.16630
M3 - Article
C2 - 34626489
AN - SCOPUS:85116569571
SN - 0269-2813
VL - 54
SP - 1416
EP - 1431
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 11-12
ER -